Efalizumab in the treatment of psoriasis

Author： Della Croce Christine Kwan Wong Vicky Lebwohl Mark G

ISSN： 1475-0708

Source： Therapy, Vol.1, Iss.2, 2004-11, pp. : 197-202

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efalizumab: A Biological Agent for the Treatment of Psoriasis

Reviews on Recent Clinical Trials, Vol. 1, Iss. 2, 2006-05 ,pp. : 165-168

Bentham Science Publishers

Access to resources Recommend Favorite

Monoclonal gammopathy of undetermined significance (MGUS) in patients with psoriasis may be associated with long‐term treatment with efalizumab, but not with anti‐TNF‐α treatments or ustekinumab

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 29, Iss. 3, 2015-03 ,pp. : 609-611

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Review of the Treatment of Psoriasis with Infliximab

Reviews on Recent Clinical Trials, Vol. 1, Iss. 3, 2006-09 ,pp. : 201-205

Bentham Science Publishers

Access to resources Recommend Favorite

Small Molecules in the Treatment of Psoriasis

DRUG DEVELOPMENT RESEARCH, Vol. 76, Iss. 5, 2015-08 ,pp. : 215-227

John Wiley & Sons Inc

Access to resources Recommend Favorite

New treatment for tackling plaque psoriasis

PRESCRIBER, Vol. 26, Iss. 20, 2015-10 ,pp. : 12-14

John Wiley & Sons Inc

Access to resources Recommend Favorite